国际流行病学传染病学杂志
國際流行病學傳染病學雜誌
국제류행병학전염병학잡지
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY AND INFECTIOUS DISEASE
2011年
2期
78-82
,共5页
黄劲松%金洁%叶卫江%俞海燕
黃勁鬆%金潔%葉衛江%俞海燕
황경송%금길%협위강%유해연
血浆置换%吸附%血液滤过%肝,人工%肝炎,重型%治疗
血漿置換%吸附%血液濾過%肝,人工%肝炎,重型%治療
혈장치환%흡부%혈액려과%간,인공%간염,중형%치료
Plasma exchange%Adsorption%Hemofiltration%liver,artificial%Severe hepatitis%Therapy
目的 探讨两种新型非生物型人工肝,即缓慢性血浆置换(PE)同步并联静脉-静脉血液滤过(CVVH)和配对血浆置换滤过吸附(CPEFA)治疗慢性乙型重型肝炎患者的临床疗效.方法 130例患者随机分成3组,A组44例,B组43例,C组43例.A组在内科综合治疗基础上加用缓慢性PE同步并联CVVH治疗,B组在内科综合治疗基础上加用CPEFA治疗,C组在内科综合治疗基础上加用单纯PE治疗.观察3组治疗前后临床症状、体征、肝功能指标、血钠浓度及近期有效率、生存率.结果 治疗结束时3组中多数患者的症状、体征有不同程度好转,肝功能主要指标明显改善.A、B两组低钠血症改善,近期有效率(治疗后6个月内)分别为70.45%和72.09%.两组间比较差异无统计学意义(χ2=0.10,P>0.05),6个月生存率分别为45.45%和46.51%,差异无统计学意义(χ2=0.08,P>0.05);C组低钠血症无改善,近期有效率51.16%,与A、B两组比较,差异有统计学意义(χ2=7.55、9.31,P<0.01),6个月生存率为30.23%,与A、B两组比较,差异有统计学意义(χ2=4.80、6.10,P<0.05).结论 缓慢性PE同步并联CVVH和CPEFA是两种新型、安全、有效的非生物型人工肝治疗方法.
目的 探討兩種新型非生物型人工肝,即緩慢性血漿置換(PE)同步併聯靜脈-靜脈血液濾過(CVVH)和配對血漿置換濾過吸附(CPEFA)治療慢性乙型重型肝炎患者的臨床療效.方法 130例患者隨機分成3組,A組44例,B組43例,C組43例.A組在內科綜閤治療基礎上加用緩慢性PE同步併聯CVVH治療,B組在內科綜閤治療基礎上加用CPEFA治療,C組在內科綜閤治療基礎上加用單純PE治療.觀察3組治療前後臨床癥狀、體徵、肝功能指標、血鈉濃度及近期有效率、生存率.結果 治療結束時3組中多數患者的癥狀、體徵有不同程度好轉,肝功能主要指標明顯改善.A、B兩組低鈉血癥改善,近期有效率(治療後6箇月內)分彆為70.45%和72.09%.兩組間比較差異無統計學意義(χ2=0.10,P>0.05),6箇月生存率分彆為45.45%和46.51%,差異無統計學意義(χ2=0.08,P>0.05);C組低鈉血癥無改善,近期有效率51.16%,與A、B兩組比較,差異有統計學意義(χ2=7.55、9.31,P<0.01),6箇月生存率為30.23%,與A、B兩組比較,差異有統計學意義(χ2=4.80、6.10,P<0.05).結論 緩慢性PE同步併聯CVVH和CPEFA是兩種新型、安全、有效的非生物型人工肝治療方法.
목적 탐토량충신형비생물형인공간,즉완만성혈장치환(PE)동보병련정맥-정맥혈액려과(CVVH)화배대혈장치환려과흡부(CPEFA)치료만성을형중형간염환자적림상료효.방법 130례환자수궤분성3조,A조44례,B조43례,C조43례.A조재내과종합치료기출상가용완만성PE동보병련CVVH치료,B조재내과종합치료기출상가용CPEFA치료,C조재내과종합치료기출상가용단순PE치료.관찰3조치료전후림상증상、체정、간공능지표、혈납농도급근기유효솔、생존솔.결과 치료결속시3조중다수환자적증상、체정유불동정도호전,간공능주요지표명현개선.A、B량조저납혈증개선,근기유효솔(치료후6개월내)분별위70.45%화72.09%.량조간비교차이무통계학의의(χ2=0.10,P>0.05),6개월생존솔분별위45.45%화46.51%,차이무통계학의의(χ2=0.08,P>0.05);C조저납혈증무개선,근기유효솔51.16%,여A、B량조비교,차이유통계학의의(χ2=7.55、9.31,P<0.01),6개월생존솔위30.23%,여A、B량조비교,차이유통계학의의(χ2=4.80、6.10,P<0.05).결론 완만성PE동보병련CVVH화CPEFA시량충신형、안전、유효적비생물형인공간치료방법.
Objective To explore the clinical effects of two new treatment methods of non-biologic artificial liver [slower plasma exchange (PE) combined with continuous veno-venous hemofiltration (CWH), and coupled plasma exchange filtration adsorption (CPEFA)] in treatment of chronic severe hepatitis B patients. Methods 130 patients with chronic severe hepatitis B were divided into three groups. 44 patients were treated with a parallel circuit of being combined slower PE and CWH based on the conservation medical therapy (group A). 43 patients were treated with CPEFA based on the conservation medical therapy (group B). 43 patients received PE with conservative medical therapy (group C). The clinical symptoms, signs, liver function, blood sodium concentration, effective rates and survival rates in three groups were surveyed before and after treatment. Results The symptom and signs of the majority in the above different groups improved. In group A and B, hyponatremia of patients were improved, the effective rates (within 6 months after the treatment) were 70.45% and 72.09% respectiverly. There was no statistical difference between the two groups (χ2=0.10,P>0.05), the survival rates(6 months) were 45.45% and 46.51% respectively and there was no statistical difference (χ2 = 0.08, P > 0.05). In group C, patients' hyponatremia did not change, the effective rate (51.16%)was obviously lower than those in group A and B (χ2 = 7.55,9.31, P < 0.01) and the total survival rate(6 months) was 30.23% also lower than those in group A, B (χ2 = 4.80,6.10, P < 0.05). Conclusions Being combined slower PE and CWH with a parallel circuit and CPEFA are two new, safe and effective methods of non-biologic artificial liver treatment.